Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -28.50%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
Codexis demonstrated strong progress in its ECO Synthesis platform and Pharma Biocatalysis business, positioning itself for revenue growth and reduced losses. However, challenges remain in revenue generation without PAXLOVID and improving gross margins.Company Guidance
In the recent Codexis earnings call for the fourth quarter and full year 2024, the company provided guidance for 2025, projecting total revenue between $64 million and $68 million, an increase from the $59.3 million earned in 2024. The guidance underscores the anticipated growth driven by their ECO Synthesis platform and a double-digit growth expectation for the entire revenue base. The company aims to transition its ECO Synthesis technology from development to commercial execution, with plans to sign revenue-generating contracts for siRNA manufacturing services by early Q2. Codexis expects significant contributions from their Pharma Biocatalysis business and new agreements, including a longer-term partnership with Pfizer. They project the back half of 2025 to experience substantial revenue growth as new contracts translate into financial results. The company ended 2024 with $73.5 million in cash and plans to achieve cash flow positivity by the end of 2026.Progress in Enzymatic siRNA Synthesis
Codexis made significant strides in enzymatic siRNA synthesis, showcasing the ECO Synthesis platform, which includes synthesizing inclisiran through various methods. They completed feasibility studies with leading siRNA innovator companies, preparing for revenue-generating contracts in Q2 2025.
Strong Traction in Pharma Biocatalysis
Codexis expanded its reach in the Pharma Biocatalysis sector, particularly with mid-tier pharma and large biotech segments, achieving commercial success and establishing new dialogues with existing customers.
Revenue Guidance for 2025
The company guided total 2025 revenue to range between $64 million to $68 million, expecting double-digit growth across its entire business base, driven by the ECO Synthesis platform and Pharma Biocatalysis.
Significant Reduction in Net Loss
Net loss for 2024 was reduced to $65.3 million from $84.4 million in the previous year, indicating improved financial management and cost reduction efforts.
---
CDXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CDXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $3.93 | $3.04 | -22.65% |
| Oct 31, 2024 | $3.14 | $3.50 | +11.46% |
| Aug 08, 2024 | $3.15 | $2.80 | -11.11% |
| May 02, 2024 | $3.34 | $3.92 | +17.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Codexis (CDXS) report earnings?
Codexis (CDXS) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Codexis (CDXS) earnings time?
Codexis (CDXS) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDXS EPS forecast?
CDXS EPS forecast for the fiscal quarter 2025 (Q1) is -0.23.
---